Biogen Inc.

BIIB ·Healthcare, Drug Manufacturers - General, United States

Biogen Inc. (BIIB)

Overview

Biogen Inc. is a global biotechnology company headquartered in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Founded in 1978 and one of the world's oldest independent biotech companies, Biogen operates in the pharmaceuticals/biotechnology industry within the healthcare sector. For full-year 2025, the company reported total revenue of approximately $9.9 billion, roughly 2% higher than 2024, with GAAP diluted EPS of $8.79 and non-GAAP diluted EPS of $15.28. Biogen employs several thousand people worldwide and is in the midst of building a new global headquarters and innovation hub in Kendall Square, Cambridge, reflecting its continued commitment to its home base even as it navigates a period of portfolio transition.

What They Do & How They Make Money

Biogen makes money by researching, manufacturing, and selling branded prescription drugs that treat chronic, often rare or severe, neurological conditions — multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, ALS, and other rare neuromuscular disorders. Because most of these are long-term, sometimes lifelong therapies, a large share of revenue is recurring: once a patient starts on a Biogen drug, they typically remain on it (or a related product) for years. Revenue is generated primarily through direct sales to specialty pharmacies, hospitals, and infusion centers, with pricing negotiated against and constrained by insurers, government payers (including Medicare, since U.S. drug-price negotiation now touches several large biopharma products), and pharmacy-benefit managers. Biogen also earns revenue-sharing and collaboration income, most notably from its long-standing partnership with Eisai on Alzheimer's drugs Leqembi and (formerly) Aduhelm, and it licenses out biosimilar versions of therapies like Rituxan, Herceptin, and Tysabri-adjacent products through partnerships. Profitability hinges on the durability of patent protection: as older multiple sclerosis drugs like Tecfidera face generic erosion, Biogen must replace that cash flow with newer, higher-priced rare-disease and Alzheimer's products, which is the central strategic tension driving the company today.

Business Segments

Biogen does not report discrete geographic or divisional segments in the way a diversified conglomerate does; instead, it manages and discloses performance by therapeutic franchise/product family within a single operating segment. The practical groupings, based on its 10-K and investor disclosures, are:

Multiple Sclerosis (MS): Historically Biogen's largest franchise, including Tysabri, Vumerity, Tecfidera, Avonex, and Plegridy. These are mature products facing generic and branded competition (e.g., from Novartis's Kesimpta and Roche's Ocrevus), and they continue to generate substantial but declining cash flow that funds newer programs.
Alzheimer's Disease: Leqembi (lecanemab), co-developed and co-commercialized with Eisai, is Biogen's primary growth driver — Q4 2025 in-market sales were roughly $134 million globally, up 54% year-over-year, with an FDA Priority Review underway for a subcutaneous (IQLIK) formulation.
Neuromuscular and Rare Disease: Spinraza (spinal muscular atrophy, competing with Roche's Evrysdi and Novartis's Zolgensma), Skyclarys (Friedreich's ataxia, acquired via the 2023 Reata Pharmaceuticals acquisition), Qalsody (SOD1-ALS), and Zurzuvae (postpartum depression, partnered with Sage Therapeutics). This is Biogen's fastest-growing and most diversified segment, with Skyclarys generating roughly $89 million in U.S. Q4 2025 revenue and patient counts up about 30% for the year.
Biosimilars: Lower-margin biosimilar versions of oncology and immunology biologics, providing revenue diversification outside neurology but playing a smaller strategic role.

Biogen does not publicly break out segment-level profit margins in granular detail; profitability commentary is generally given at the consolidated level, with growth products (Leqembi, Skyclarys, Zurzuvae, Qalsody) collectively cited as up about 19% for full-year 2025.

Competitors

Multiple Sclerosis: Roche/Genentech (Ocrevus), Novartis (Kesimpta), Bristol Myers Squibb (Zeposia), Sanofi (Aubagio), and generic manufacturers competing against Tecfidera.
Alzheimer's Disease: Eli Lilly (Kisunla/donanemab) is Biogen and Eisai's most direct rival in the anti-amyloid market; longer-term competitive and adjacent pressure also comes from companies developing tau-targeting and other disease-modifying approaches.
Spinal Muscular Atrophy / Rare Disease: Roche (Evrysdi) and Novartis (Zolgensma) compete directly with Spinraza; PTC Therapeutics and other rare-disease specialists compete in adjacent niches.
Biosimilars: Amgen, Sandoz (Novartis), Pfizer, and other large-scale biosimilar manufacturers.
Broader industry peers: UCB, Alexion (AstraZeneca), Ionis Pharmaceuticals, and Alnylam Pharmaceuticals (also Cambridge-based) compete for specialist mindshare, trial talent, and payer attention in neurology and rare disease more broadly.

Competitive Position

Biogen's moat rests on deep, decades-long expertise in neuroscience R&D, an established global commercial infrastructure for reaching neurologists and specialty pharmacies, and a diversified rare-disease pipeline that offers pricing power and lower competitive intensity than its legacy MS business. Its partnership model (with Eisai on Alzheimer's, Sage on Zurzuvae, Ionis on Spinraza and Qalsody) also lets it share R&D risk and cost while retaining significant commercial upside. The company's central challenge is franchise transition: its once-dominant multiple sclerosis products are in structural decline from generic and branded competition, and the company must prove that Leqembi, Skyclarys, Qalsody, and Zurzuvae can collectively replace that lost revenue and return Biogen to sustained top-line growth. Key risks include continued MS erosion outpacing new-product ramp, the commercial complexity of Alzheimer's diagnosis and treatment infrastructure (amyloid PET/CSF testing, infusion capacity, ARIA safety monitoring) limiting Leqembi's uptake, pricing and reimbursement pressure from U.S. drug-price negotiation and international reference pricing, patent-cliff and biosimilar exposure, and binary clinical-trial risk across its early- and mid-stage pipeline (including litifilimab, which recently received Breakthrough Therapy Designation for cutaneous lupus). Biogen's continued investment in a new Cambridge headquarters signals confidence in its long-term neuroscience strategy, but its stock and reputation remain sensitive to quarterly execution on the Alzheimer's and rare-disease growth story.